2022
Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1
Rischka L, Murgaš M, Pichler V, Vraka C, Rausch I, Winkler D, Nics L, Rasul S, Silberbauer LR, Reed MB, Godbersen GM, Unterholzner J, Handschuh P, Gryglewski G, Mindt T, Mitterhauser M, Hahn A, Ametamey SM, Wadsak W, Lanzenberger R, Hacker M. Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1. EJNMMI Research 2022, 12: 53. PMID: 36018389, PMCID: PMC9418393, DOI: 10.1186/s13550-022-00925-8.Peer-Reviewed Original ResearchExtrasynaptic NMDA receptorsStandardized uptake valueNMDA receptorsUrinary bladderEffective dose coefficientsPET radioligandNeuropsychiatric disordersTreatment monitoringSynaptic NMDA receptorsTime-integrated activity coefficientsCentral nervous systemUrinary bladder contentsDrug developmentDose coefficientsAdverse eventsExcitotoxic processTRIAL REGISTRATIONBladder contentsHealthy subjectsSynaptic transmissionSide effectsBone marrowNervous systemUptake valueEffective dose
2017
Administration of ketamine for unipolar and bipolar depression
Kraus C, Rabl U, Vanicek T, Carlberg L, Popovic A, Spies M, Bartova L, Gryglewski G, Papageorgiou K, Lanzenberger R, Willeit M, Winkler D, Rybakowski JK, Kasper S. Administration of ketamine for unipolar and bipolar depression. International Journal Of Psychiatry In Clinical Practice 2017, 21: 2-12. PMID: 28097909, DOI: 10.1080/13651501.2016.1254802.Peer-Reviewed Original ResearchConceptsBipolar depressionSide effectsResponse rateMost common side effectsLong-term side effectsHamilton Depression Rating ScaleAntidepressant response ratesNausea/vomitingOpen-label trialRapid antidepressant efficacyTreatment-resistant depressionAnti-suicidal effectsCommon side effectsEfficacious treatment optionPrimary outcome measureAdministration of ketamineDepression Rating ScaleNew administration routesWeb of ScienceKetamine efficacyResistant depressionAntidepressant efficacyRelapse rateAntidepressant responseSafety profile